Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. [electronic resource]
Producer: 20040819Description: 1718-23 p. digitalISSN:- 1524-4539
- Anti-Inflammatory Agents, Non-Steroidal -- administration & dosage
- Antibodies, Antineutrophil Cytoplasmic -- analysis
- Antibodies, Monoclonal -- administration & dosage
- Autoimmune Diseases -- blood
- C-Reactive Protein -- analysis
- Churg-Strauss Syndrome -- blood
- Cohort Studies
- Cyclophosphamide -- administration & dosage
- Drug Therapy, Combination
- Endothelium, Vascular -- drug effects
- Enzyme Inhibitors -- pharmacology
- Female
- Forearm -- blood supply
- Granulomatosis with Polyangiitis -- blood
- Humans
- Immunosuppressive Agents -- administration & dosage
- Infliximab
- Interleukin-6 -- blood
- Male
- Middle Aged
- Mycophenolic Acid -- administration & dosage
- Nitric Oxide -- blood
- Nitric Oxide Synthase -- antagonists & inhibitors
- Nitric Oxide Synthase Type III
- Pilot Projects
- Plethysmography
- Prednisolone -- administration & dosage
- Regional Blood Flow -- drug effects
- Tumor Necrosis Factor-alpha -- analysis
- Vasculitis -- blood
- omega-N-Methylarginine -- pharmacology
No physical items for this record
Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.